Brazil: The patent combination conundrum

Patents to new medicines usually protect the active ingredient (compound), provided that it is new and inventive. It is also a common practice for pharmaceutical companies to seek patent protection for drug combinations, which can be especially valuable for providing a competitive advantage over other companies that are developing single-component drugs.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Atif Choudhury at achoudhury@lifesciencesipreview.com

More on this story

Americas

Court upholds $83m sequencing verdict and sets royalty rate

17 June 2026 A cancer diagnostics company has lost its bid to overturn a jury verdict in a major patent dispute that has also spawned parallel proceedings before the Federal Circuit and PTAB.

Americas

Amgen and subsidiary dealt $20m blow over rodent antibody tech

15 June 2026 Unanimous jury finds willful infringement, with the possibility of a trebled award and a much larger feud still to come.

Americas

Moderna: BioNTech is claiming work ‘it never did’

12 June 2026 In a strong response to BioNTech, Moderna argues its next-gen vaccine is built on a fundamentally different design from the German biotech’s—setting up a scrap over whether a key patent should have been granted.

More features

Court upholds $83m sequencing verdict and sets royalty rate

Amgen and subsidiary dealt $20m blow over rodent antibody tech

Moderna: BioNTech is claiming work ‘it never did’

MoFo bags IP trial duo with 50 years’ combined experience

US biotech fires trade secrets suit at Chinese pharma group

Hikma v Amarin: Six takeaways from the pivotal ruling

Fed Circ rejects Nexus’ appeal in generics row with biopharma firm

Hikma triumphs at SCOTUS in landmark skinny-label ruling

Brazil: The patent combination conundrum

More on this story

Editor's picks

Editor's picks

More features